-
Momenta Pharmaceuticals Announces Completion of Proposed Sale to Johnson & Johnson
01 Oct 2020 12:44 GMT
CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA, “Momenta” or the “Company”), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, …
-
Momenta Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period in Connection with Proposed Sale to Johnson & Johnson
15 Sep 2020 12:00 GMT
CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA, “Momenta” or the “Company”), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, …
-
Lifshitz Law Firm, P.C. Announces Investigation of Cancer Genetics, Inc., Momenta Pharmaceuticals, Inc., Principia Biopharma Inc., and Yintech Investment Holdings Limited
01 Sep 2020 23:17 GMT
… -mail at info@jlclasslaw.com.
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)
Lifshitz Law … at info@jlclasslaw.com.
ATTORNEY ADVERTISING.© 2020 Lifshitz Law Firm, P …
-
SHAREHOLDER ALERT: WeissLaw LLP Investigates Momenta Pharmaceuticals, Inc.
20 Aug 2020 02:17 GMT
… 47;www.weisslawllp.com/momenta-pharmaceuticals-inc/
Or please … information), consumer fraud (including false advertising, defective products, or other … shareholder-alert-weisslaw-llp-investigates-momenta-pharmaceuticals-inc-301115235.html
SOURCE …
-
(MNTA) Alert: Johnson Fistel Investigates Proposed Sale of Momenta Pharmaceuticals; Are Shareholders Getting a Fair Price?
19 Aug 2020 15:32 GMT
… whether the board members of Momenta Pharmaceuticals, Inc. ("Momenta" or … ;/www.johnsonfistel.com. Attorney advertising. Past results do not guarantee … -fistel-investigates-proposed-sale-of-momenta-pharmaceuticals-are-shareholders-getting-a-fair …
-
MOMENTA PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout
19 Aug 2020 16:59 GMT
… . announces that it is investigating Momenta Pharmaceuticals, Inc. (“Momenta”) (NASDAQ GS: … ;www.rigrodskylong.com/cases-momenta-pharmaceuticals-inc. If you would … corporate class actions nationwide. Attorney advertising. Prior results do not …
-
Momenta Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Nipocalimab in HDFN
28 Jul 2020 11:15 GMT
CAMBRIDGE, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced that its novel drug candidate, nipocalimab, has received rare pediatric disease designation from the U.S. Food and Drug Administration (FDA) …
-
Momenta Pharmaceuticals Announces Positive Topline Data from Interim Analysis of Phase 2 Vivacity-MG Study of Nipocalimab (M281) in Generalized Myasthenia Gravis (gMG)
15 Jun 2020 11:05 GMT
- Trial met primary endpoint with a strong relationship between Immunoglobulin G (IgG) reduction and MG-ADL clinical benefit (p<0.0001) -
- Nipocalimab induced a rapid and durable response in the myasthenia gravis activities of daily living score …
-
Momenta Pharmaceuticals Appoints Dr. Jane F. Barlow to Board of Directors
13 Dec 2019 13:00 GMT
CAMBRIDGE, Mass., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced the appointment of Jane F. Barlow, M.D., M.P.H., M.B.A. to its Board of Directors.
“Dr. Barlow’s expertise in market access and commercial …
-
Momenta Pharmaceuticals Announces Pricing of Public Offering of Common Stock
12 Dec 2019 13:00 GMT
CAMBRIDGE, Mass., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced the pricing of its underwritten public offering of 14,516,130 shares of its common stock at the public offering price of $15.50 per share for …
About
© 1995-2025